PolyPid (PYPD) Stock Forecast & Price Target

PolyPid is attractive because D-PLEX100 has replicated pivotal efficacy, cutting incisional surgical-site infections by about 60% in SHIELD II, while the NDA is under Priority Review with a November 28, 2026 PDUFA date and only narrow remaining CMC and inspection risk. The company also de-risks commercialization through Azurity, which has already paid $30M, will fund the launch, and gives PolyPid tiered mid-teen to mid-20% royalties plus manufacturing and transfer-price economics, making the current ~$100M EV appear to understate the asset’s value. With a measured launch expected in 2027, potential NTAP support from 4Q27, and runway into 2028 without immediate financing needs, the setup combines clinical validation, non-dilutive cash, and capital-light recurring revenue.

PolyPid is viewed negatively because D-PLEX100 still faces major regulatory and commercialization risk, with a November 28, 2026 PDUFA date, the possibility of a CRL or restrictive label, and manufacturing exposure tied to Israeli production and FDA inspection outcomes. Even if approved, reimbursement is uncertain because Azurity has applied for FY2028 NTAP but approval is not assured, and a denial could leave hospitals absorbing full costs, slowing P&T reviews and limiting adoption. The thesis is further weakened by dependence on Azurity’s execution, undisclosed royalty and milestone economics, concentrated exposure to D-PLEX100, and the risk that delays or weaker uptake force dilutive financing, especially after the stock fell ~27% on the announcement.